# Human HLA-A\*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein






Description	
Source	Recombinant Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
	It contains Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and VYFFLPDHL peptide.
Accession	AAA59600.1(HLA-A*24:02)&P61769(B2M)&VYFFLPDHL
Molecular Weight	The protein has a predicted MW of 50.40 kDa. Due to glycosylation, the protein migrates to 55-63 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and Storage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100.

# **Assay Data**

#### **Bis-Tris PAGE**



Human HLA-A\*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


**SEC-HPLC** 

# Human HLA-A\*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein

Cat. No. MHC-HM433



# **Assay Data**



The purity of Human HLA-A\*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer is greater than 95% as determined by SEC-HPLC.